Renoprotective Effect of the Combined Use of Steroid and Angiotensin II Receptor Blocker in IgA Nephropathy.
- Author:
Young Ki KIM
1
;
Sang Ho LEE
;
Tae Won LEE
;
Myung Jae KIM
;
Moon Ho YANG
;
Chun Gyoo IHM
Author Information
1. Department of Internal Medicine, College of Medicine, Kyung Hee University, Seoul, Korea. cgihm@yahoo.co.kr
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Angiotensin II receptor blocker;
Prednisolone;
IgA nephropathy;
Proteinuria;
Renal function
- MeSH:
Angiotensin II*;
Angiotensins*;
Creatinine;
Glomerulonephritis, IGA*;
Humans;
Immunoglobulin A*;
Prednisolone;
Prospective Studies;
Proteinuria;
Receptors, Angiotensin*
- From:Korean Journal of Nephrology
2005;24(1):71-79
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Several studies have examined the role of angiotensin II receptor blocker (ARB) or steroid treatment in decreasing proteinuria and preserving renal function in IgA nephropathy (IgAN). METHODS: We designed a prospective, randomized trial to assess the effects of combination therapy of steroid (daily high-dose for 6 months) and ARB in IgAN patients with proteinuria >or=1.0 g/d and serum creatinine (SCr)or=1.4 mg/dL at the last visit had older age and higher proteinuria level at 6 mo than those with SCr<1.4 mg/dL. CONCLUSION: It was observed in the patients with IgAN with normal renal function and proteinuria >or=1g/d that the combination of ARB and prednisolone was more effective in preserving renal function as well as in decreasing proteinuria than the ARB alone therapy.
